Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma

Document Details

Document Type
Pub Defense Publication
Publication Date
Nov 01, 2022
Source ID
10.1016/j.ygyno.2022.08.006

Entities

People

  • Ainhoa Madariaga
  • Amit M. Oza
  • Janelle Ramsahai
  • Judy Quintos
  • Karen Chang
  • Katherine Karakasis
  • Lisa Wang
  • Neesha C. Dhani
  • Nisan Kavak
  • Sandra A. Mitchell
  • Stephanie Lheureux
  • Stephen A. Welch
  • Tyler Pittman
  • Valerie Bowering

Organizations

  • AstraZeneca
  • National Cancer Institute
  • Princess Margaret Cancer Foundation
  • United States Department of Defense